Proposal
South Korea plans to define the scope of genetic material for biopharmaceuticals
South Korea is seeking public feedback on defining the scope of genetic material in advanced biopharmaceuticals.
If you work in the advanced regenerative medicine or advanced biopharmaceutical sectors in South Korea, this proposal concerns you. The Ministry of Health and Welfare is planning to define the specific scope of "genetic material" to be included under the definition of "human cells, etc." following recent changes to the law.
What to do: If you have opinions on this definition, you can submit them online via the National Participation Legislation Center or by mail, email, or fax to the Ministry of Health and Welfare by 9 November 2026.
What we do not know: The exact technical boundaries of the genetic material included in this scope and how this specific definition will impact existing research or manufacturing protocols.
Headlines and summaries are written by AI for Outer News (RS Elite Pro s.r.o.) from the official text and are not reviewed by a person. They are not the official text and can contain mistakes: before you rely on one, read the original.
Original title: 첨단재생의료 및 첨단바이오의약품 안전 및 지원에 관한 법률 시행령 일부개정령안 재입법예고
Read the official decisionSource: Ministry of Government Legislation